Ishiguro H, Masuda N, Sato N, Higaki K, et al. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Res Treat 2020 Mar 13. pii: 10.1007/s10549-020-05590.
PMID: 32170634